See more : CEVA, Inc. (CEVA) Income Statement Analysis – Financial Results
Complete financial analysis of Eliem Therapeutics, Inc. (ELYM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eliem Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sartorius Aktiengesellschaft (0NIQ.L) Income Statement Analysis – Financial Results
- Generation Asia I Acquisition Limited (GAQ-WT) Income Statement Analysis – Financial Results
- Westwood Holdings Group, Inc. (WHG) Income Statement Analysis – Financial Results
- Lebledor F&B Co., Ltd. (7757.TWO) Income Statement Analysis – Financial Results
- Canon Marketing Japan Inc. (8060.T) Income Statement Analysis – Financial Results
Eliem Therapeutics, Inc. (ELYM)
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 15.41M | 26.21M | 23.32M | 9.34M | 4.02M |
| General & Administrative | 9.89M | 18.92M | 12.35M | 2.43M | 677.00K |
| Selling & Marketing | 24.85M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.89M | 18.92M | 12.35M | 2.43M | 677.00K |
| Other Expenses | 0.00 | 1.38M | -11.64M | 0.00 | 914.00K |
| Operating Expenses | 37.41M | 45.14M | 35.67M | 11.77M | 4.70M |
| Cost & Expenses | 37.41M | 45.14M | 35.67M | 11.77M | 4.70M |
| Interest Income | 0.00 | 1.20K | 450.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.59M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 21.47M | 45.14M | 35.67M | 11.77M | 4.70M |
| EBITDA | -13.65M | -43.65M | -35.50M | -2.87M | -1.93M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.47M | -45.14M | -35.67M | -20.93M | -7.45M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.65M | -109.00K | -11.81M | 257.00K | 899.00K |
| Income Before Tax | -35.12M | -45.24M | -47.48M | -20.67M | -6.55M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -21.47K | 109.00K | -66.56K | -9.16M | -2.75M |
| Net Income | -35.12M | -45.35M | -47.48M | -11.51M | -3.80M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| EPS Diluted | -1.30 | -1.72 | -1.81 | -0.44 | -0.14 |
| Weighted Avg Shares Out | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
| Weighted Avg Shares Out (Dil) | 26.99M | 26.31M | 26.24M | 26.32M | 26.32M |
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Transaction to add clinical-stage program directed towards treating unmet needs in autoantibody-mediated diseases Combined company expected to have approximately $210 million of cash and cash equivalents, including $120 million from a concurrent private placement of common stock from leading life...
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
Why Is Eliem Therapeutics (ELYM) Stock Up 6% Today?
Eliem Therapeutics (NASDAQ: ELYM ) stock is taking off on Thursday after the biotechnology company announced plans to explore strategic alternatives. Eliem Therapeutics came to this decision after completing a review of the company and its various programs.
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itself
Eliem Therapeutics Inc.'s stock ELYM, -4.76% soared 21% in premarket trade Thursday, after the biotech, which specializes in therapies for neuronal excitability disorders, said it is exploring its strategic options. The Seattle and Cambridge, U.K.-based company said it has halted...
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
SEATTLE and CAMBRIDGE, United Kingdom, July 20, 2023 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM) today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, and has made the...
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other...
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
5 Short Squeeze Candidates To Watch This Week: TherapeuticsMD Tops List While This Arts And Crafts Retailer Joins The Leaderboard
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
5 Short Squeeze Candidates To Watch This Week: Vertex Energy Tops List, Medavail Holdings And Camping World Remain Elevated
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
Eliem Therapeutics shares sink more than 50% after lead program fails to show benefit in clinic
Shares of Eliem Therapeutics fell more than 50% Monday after reporting disappointing clinical data.
Source: https://incomestatements.info
Category: Stock Reports